



Reimagining AI in Biopharma

*Tom Chittenden, PhD, DPhil, PStat
Chief Scientific Officer, President of R&D, SAB Chairman
Lecturer on Pediatrics, BCH & Harvard Medical School*

**The Lab of the Future Congress USA
10 March 2023**

AI/SciML Platform for Drug Discovery and Drug Development

Generative AI/ML models for **cell differentiation** and unsupervised clinical & phenotype data integration and **phenomapping**

Functional enrichment & advanced **Natural language processing (NLP)** of published research literature

Domain adaptation and **transfer learning** methods for cross-species and/or cross-cohort signal acquisition

Novel NLP embeddings for advanced feature learning/engineering

Novel causal inference and **qML models**

Advanced deep convolutional **neural network** topologies

Discovery

Pre-Clinical

Clinical

Commercial


- Analysis of **Single Cell** data
- Analysis of **multi-omic** data
- Class assignment for omics & phenotypic patient cohort data
- **Drug target discovery**

- Biological interpretation of AI/ML findings

- **Drug repositioning**
- **Analysis of RWE data**
- **MOA**
- **Drug efficacy assessment in clinical trials**

- Digital pathology, medical image analysis for **radiogenomics** & patient inclusion/ exclusion criteria for clinical trials

Scientific Impact in the Biomedical Sciences




Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort [link](#)

Featured on Cover




Enhancing retrosynthetic reaction prediction with Deep Learning Using multiscale reaction classification [link](#)

Featured on Cover
Accompanying Editorial



Quantum processor-inspired machine learning in the biomedical sciences [link](#)

Featured at NHLBI



Smooth muscle cell reprogramming in aortic aneurysms [link](#)

Featured on Cover
Accompanying Editorial




Somatic mutation in single human neurons tracks developmental and transcriptional history [link](#)

Accompanying Editorial



Chronic mTOR activation induces a degradative smooth muscle cell phenotype [link](#)

Accompanying Editorial



Endothelial TGF- β signaling drives vascular inflammation and atherosclerosis [link](#)

Accompanying Editorial




Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium [link](#)

Accompanying Editorial



Aging & neurodegeneration are associated with increased mutations in single human neurons [link](#)



Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification [link](#)

Ensemble AI/SciML and Precision Medicine

The computational power of modern AI/ML technology is well-positioned to uncover new and actionable insights from the exponentially growing pool of biological data.



FEATURE LEARNING

The intelligent simplification of high-dimensional multi-omic data without loss of information

ENSEMBLE MACHINE & DEEP LEARNING

Intelligent algorithms capable of self-optimization to achieve incredible accuracy with complex, layered data

CAUSAL INFERENCE

Specialized statistical learning models capable of elucidating causal dependencies within biological data

NATURAL LANGUAGE PROCESSING

Intelligent scanning of sentence syntax to understand and validate findings in context, at scale


The combination of several AI/SciML methods create a proprietary ensemble AI/SciML strategy capable of revealing novel patterns and causal dependencies in disparate and varied biological data.

COVID-19 Severity Study: Ensemble AI/SciML/qML approach to compare critical vs non-critical patients

- Unique study design focused on adults younger than 50 without co-morbidities or age-related decline
- During height of first wave (before corticosteroid use), our collaborators at Strasbourg recruited COVID-19 patients with ARDS requiring mechanical ventilation and matched patients who were sick enough to be hospitalized but required oxygen without assisted ventilation

Group	Description	Whole blood RNA-Seq	Plasma Proteomics	PBMC Proteomics	WGS
Critical	Severe COVID patients with ARDS requiring ventilators	46	45	34	47
Non-critical	Control COVID patients hospitalized and given oxygen but not ICU care	23	23	21	25
COVID negative controls	Healthy controls from blood donors at same hospital	22	22	22	22

Cohort 1 RNA-seq: Critical(ARDS) vs non-critical groups with ensemble strategy comprising 7 different AI/ML algorithms including Quantum SVM (69 patients total) – Leads to stable gene feature sets to allow for subsequent causal inference (other methods produce variable gene lists)




High accuracies with AUROC of test sets from 0.94 to 0.99

	LASSO	Ridge	SVM	qSVM
Accuracy (Train/Test)	0.9991 ± 0.0004 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9245 ± 0.0028	1.0000 ± 0.0000 / 0.8677 ± 0.0121	
Balanced Acc. (Train/Test)	0.9987 ± 0.0006 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9189 ± 0.0039	1.0000 ± 0.0000 / 0.9223 ± 0.0075	
AUROC (Train/Test)	1.0000 ± 0.0000 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9667 ± 0.0029	1.0000 ± 0.0000 / 0.9908 ± 0.0036	1.0000 ± 0.0000 / 0.9386 ± 0.0081
F1 (Train/Test)	0.9993 ± 0.0003 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9426 ± 0.0020	1.0000 ± 0.0000 / 0.9780 ± 0.0034	1.0000 ± 0.0000 / 0.9095 ± 0.0071
MCC (Train/Test)	0.9980 ± 0.0009 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.8339 ± 0.0065	1.0000 ± 0.0000 / 0.9251 ± 0.0118	1.0000 ± 0.0000 / 0.7398 ± 0.0198

	XGB	RF	DANN	
Accuracy (Train/Test)	0.9952 ± 0.0008 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9254 ± 0.0072	1.0000 ± 0.0000 / 0.9146 ± 0.0076	1.0000 ± 0.0000 / 0.9131 ± 0.0083
Balanced Acc. (Train/Test)	0.9930 ± 0.0012 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.8932 ± 0.0100	1.0000 ± 0.0000 / 0.9072 ± 0.0094	1.0000 ± 0.0000 / 0.9032 ± 0.0097
AUROC (Train/Test)	0.9999 ± 0.0000 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9443 ± 0.0079	1.0000 ± 0.0000 / 0.9360 ± 0.0091	1.0000 ± 0.0000 / 0.9435 ± 0.0081
F1 (Train/Test)	0.9964 ± 0.0006 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.9391 ± 0.0054	1.0000 ± 0.0000 / 0.9467 ± 0.0052	1.0000 ± 0.0000 / 0.9359 ± 0.0062
MCC (Train/Test)	0.9893 ± 0.0018 / 1.0000 ± 0.0000	1.0000 ± 0.0000 / 0.8061 ± 0.0181	1.0000 ± 0.0000 / 0.8308 ± 0.0168	1.0000 ± 0.0000 / 0.8091 ± 0.0185


Integrated AI/SciML and Structural Causal Modeling on top of 600 RNA-seq genes from critical (ARDS) vs non-critical groups

Putative flow of Causal Dependency






COVID-19 project – Experimental Validation of AI/SciML Findings (effects of ADAM9 silencing on viral uptake and replication)

- Silencing Gene X inhibits SARS-CoV-2 uptake and replication in human lung epithelial cells: ***strong empirical evidence of molecular mechanism of action driving complex disease etiology***
- Actively pursuing a possible **first AI/ML-based repositioning** of a drug currently in Phase III trials ADAM9+ tumors




Carapito, R et al., *Science Translational Medicine* 2021



In Silico Phenotype Projection: Identifying Causal Drivers of CVD (Hypertension, Vascular Hemorrhage, and Renal Failure)

(Ricard et al., *JEM* 2019)



Example of integrated in vitro *supervised* classification and structural causal modeling (SCM) of bulk RNA-seq data to predict in vivo phenotype. [Analogous to reverse genetics with added systems biology context](#)

Research Collaboration with Yale Cardiovascular Research Center



Deep Learning, Structural Causal Modeling, and NLP of Bulk and Single Cell RNA-seq Data

In Silico Phenotype Projection: Identifying Causal Drivers of CVD (Hypertension, Vascular Hemorrhage, and Renal Failure)

Example of causal structural modeling (SCM) of bulk RNA-seq analysis, which is downstream


supervised bulk RNA-seq analysis on previous slide to derive putative causal drivers of disease etiology, phenotype, etc.

(Ricard et al., JEM2019)




Research Collaboration with Yale Cardiovascular Research Center
Deep Learning, Structural Causal Modeling, and NLP of Bulk and Single Cell RNA-seq Data

In Silico Phenotype Projection: Identifying Causal Drivers of CVD (Hypertension, Vascular Hemorrhage, and Renal Failure)



Research Collaboration with Yale Cardiovascular Research Center
Deep Learning, Structural Causal Modeling, and NLP of Bulk and Single Cell RNA-seq Data


A Novel AI/SciML R&D Innovation Engine



Causal AI and Digital Twin Technology Roadmap:

The future of drug target discovery and drug development

World's first Exascale Causal AI platform
(Oracle)



Acknowledgements

BioAI Health

- Alan Jerusalmi
- Michael James
- Krishna Bairavi
- Ayushi Shah
- Mike Bonham
- John Cogswell

Queen Mary University of London

- Sir Mark Caulfield
- Andrew Livingston
- Greg Slabaugh

Elucidata

- Abhishek Jha
- Devika Benoy

Biorelate

- Mark Hughes

Oracle

- Alison Derbenwick Miller
- Ryan Payton

Genuity Science

- Jeff Gulcher
- Hannes Smarason
- Judith Conroy
- Amy Swearingen

Genuity AI Research Institute

- Sweta Bajaj
- Jose Malagon Lopez
- Richard Li
- Allison McLean
- Raony Guimaraes
- Tiago Magalhaes
- Chris Hoefler

Boston Children's Hospital

Harvard Medical School

- Chris Walsh

Cardiovascular Research Center

Yale University Medical School

- Mike Simons

University of Southern California

- Daniel Lidar
- Razieh Mohseninia

University of Tennessee

Health Science Center

- Hao Chen

University of Strasbourg Medical Center

- Seiamak Bahram
- Raphael Carapito